Centrex Announces Formation of Subsidiary.Business Editors/Health/Medical Writers TULSA, Okla.--(BUSINESS WIRE)--Feb. 5, 2004 Centrex, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CNEX) today announced that in order to enhance the Company's ability to accelerate the development of the Company's Single Molecule Nucleic Acid Detection (SMD (1) (Storage Module Device) A high-performance hard disk interface used with minis and mainframes that transfers data in the 1-4 MBytes/sec range (SMD-E provides highest rate). See hard disk. ) technology Centrex, Inc., in conjunction with Trifocal trifocal /tri·fo·cal/ (tri-fo´-) (tri´fo-k'l) 1. having three foci. 2. containing one part for near vision, one for intermediate, and a third for distant vision, as a trifocal lens. LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , has formed Early Warning Technologies, Inc. Early Warning Technologies will be majority-owned by Centrex and minority-owned by Trifocal LLC. R. Scott Wills, the principal of Trifocal, will serve as CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Early Warning Technologies. Early Warning Technologies will assume the technology assets of Centrex along with certain contractual obligations with Los Alamos and the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). , and will take over the development and commercialization of the SMD technology from Centrex. This arrangement will allow Centrex to pursue other technology acquisitions and potential joint ventures. Centrex CEO, Thomas R. Coughlin, Jr. M.D. will also serve on the Board of Early Warning Technologies, and will serve as Chief Scientific and Technical Advisor for Early Warning Technologies. The agreement will require shareholder approval Scott Wills is an experienced corporate executive who has held management positions ranging from start-ups to Fortune 500 companies. He has extensive experience across a broad range of technology industries. As an entrepreneur, Mr. Wills has been involved in the management and funding of both private and public companies and has served as CEO of three other companies. Dr. Coughlin commented, "We are extremely excited about the prospect of working with a person of the caliber of Scott Wills and that Early Warning Technologies will provide the platform necessary to achieve our development goals." Centrex's SMD technology has been exclusively licensed from Los Alamos National Laboratories and represents advantages over existing DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. and RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic detection methods as well as culture-based test methods. Centrex's detection system is designed to be adaptable to detect a variety of bacterial or viral organisms by recognizing the unique DNA or RNA fingerprint of the organism. The prototype instrument, currently being developed will utilize disposable, multipurpose microfluidics lab cards that incorporate the SMD technology. For more information, visit the Centrex website at www.centrexcorporation.com or contact 843-971-4848. This press release contains certain forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our business. Those uncertainties are discussed in the Company's SEC filings. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion